NewAmsterdam Pharma Co N.V annual return on equity
2022
2023
2024
2025
NewAmsterdam Pharma Co N.V Return on Equity (ROE) Growth & History (NAMS)
NewAmsterdam Pharma Co N.V's return on equity was −28.29% for fiscal 2025.
View full NewAmsterdam Pharma Co N.V company overviewNewAmsterdam Pharma Co N.V annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −28.29% | +17.91 pp |
| 2024 | 2024-12-31 | −46.20% | +3.06 pp |
| 2023 | 2023-12-31 | −49.25% | −34.94 pp |
| 2022 | 2022-12-31 | −14.31% | — |
NewAmsterdam Pharma Co N.V quarterly return on equity
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −9.89% | −7.66 pp |
| Q1 2026 | 2026-03-31 | −7.18% | −2.03 pp |
| Q4 2025 | 2025-12-31 | −10.62% | +5.61 pp |
| Q3 2025 | 2025-09-30 | −9.56% | −5.21 pp |
| Q2 2025 | 2025-06-30 | −2.23% | +7.53 pp |
| Q1 2025 | 2025-03-31 | −5.15% | +21.63 pp |
| Q4 2024 | 2024-12-31 | −16.22% | −1.26 pp |
| Q3 2024 | 2024-09-30 | −4.34% | — |
| Q2 2024 | 2024-06-30 | −9.76% | −0.23 pp |
| Q1 2024 | 2024-03-31 | −26.78% | — |
| Q4 2023 | 2023-12-31 | −14.96% | — |
| Q2 2023 | 2023-06-30 | −9.53% | — |
NewAmsterdam Pharma Co N.V return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, NewAmsterdam Pharma Co N.V's return on equity decreased from −14.31% to −28.29%, a change of −13.98 percentage points. The latest reported quarter, Q2 2026, shows −9.89%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NewAmsterdam Pharma Co N.V source filings ↗